Last reviewed 2026-04-23 · How we verify

EDP-235

Enanta Pharmaceuticals, Inc · Phase 2 active Small molecule

At a glance

Generic name	EDP-235
Sponsor	Enanta Pharmaceuticals, Inc
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 (PHASE2)
Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects (PHASE1)
Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects. (PHASE1)
A Study of EDP-235 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results